Table 2.

Percent sensitivity of serum biomarkers for benign disease and for early stage (I-II) and late stage (III-IV) ovarian cancer at 98% specificity in healthy controls evaluated in the EDRN validation serum set.

Ag/AAb	Biomarker/Sensitivity (%)	Benign	Early	Late	All cases
	TP53 (RAPID)	0.5	12.5	25.3	22.0
	IL-8	8.5	26.5	15.6	18.4
	CTAG1	3.0	7.9	19.4	16.4
AAb
	HE4 Ag-AAb	3.0	18.8	8.6	11.2
	CA125	22.0	62.5	93.5	85.6
	HE4	0.0	40.6	86.0	74.4
Ag	OPN	4.0	12.5	22.6	20.0
	HK 6	1.0	6.3	46.7	36.3
	HK10	2.0	9.4	49.5	39.2